Inmunoterapia en el mieloma múltiple-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inmunoterapia en el mieloma múltiple

Published:2024-05 Issue:10 Volume:162 Page:485-493
ISSN:0025-7753
Container-title:Medicina Clínica
language:es
Short-container-title:Medicina Clínica

Author:

Asensi Cantó Pedro^ORCID,Arnao Herraiz Mario,de la Rubia Comos Javier^ORCID

Publisher

Elsevier BV

Reference60 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J Clin,2021

2. LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma;Mateos;Leuk.,2022

3. Teclistamab in Relapsed or Refractory Multiple Myeloma;Moreau;N Engl J Med,2022

4. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM);van de Donk;J Clin Oncol,2023

5. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results;Lesokhin;Nat Med,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3